Valiant Laboratories Ltd Stock Price Today (NSE: VALIANTLAB)
Fundamental Score
Valiant Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Valiant Laboratories Ltd share price today is ₹58.51, up +0.00% on NSE/BSE as of 19 February 2026. Valiant Laboratories Ltd (VALIANTLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹367.80 (Cr). The 52-week high for VALIANTLAB share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 72.54x, VALIANTLAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -1.43% and a debt-to-equity ratio of 0.17.
Valiant Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Valiant Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Valiant Laboratories Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, while offering the potential for high growth, also presents unique challenges. Generics, in particular, operate in a competitive landscape where pricing pressures and regulatory hurdles can significantly impact profitability. This analysis examines the current situation surrounding Valiant Laboratories share price (₹58.860001 as of the latest data), focusing on key financial metrics relevant to a conservative value investor seeking capital safety.
One of the most concerning figures is the company's Return on Capital Employed (ROCE) of -0.95%. A negative ROCE indicates that Valiant Laboratories is destroying value rather than creating it. This severely impacts the company's "moat," or its competitive advantage. Without a healthy return on invested capital, it becomes exceedingly difficult to reinvest in the business, innovate, and sustain its market position against competitors.
The Price-to-Earnings (PE) ratio of 72.54 presents another area of concern. Compared to the broader market and potentially some of its peers, this appears significantly elevated. While a high PE might be justifiable for a company with exceptional growth prospects, the negative ROCE casts doubt on Valiant Laboratories' ability to deliver the earnings growth needed to support such a valuation.
When evaluating a company, it is important to consider the quality of management. Take
Mankind Pharma Ltd, for instance. While I don't have specific inside information on either company's management team, comparing their financial performance can offer some insight. A consistently strong ROCE and profit margins at Mankind Pharma Ltd., may suggest effective capital allocation and operational excellence that Valiant Laboratories currently lacks. The stark contrast raises concerns about Valiant Laboratories' management's ability to navigate the competitive generic pharmaceutical market. A turnaround will require exceptional strategic execution.This analysis is part of a comprehensive 80-parameter fundamental audit process verified by Sweta Mishra. The focus remains on identifying potential risks and assessing the company's ability to generate sustainable value while prioritizing capital safety. This analysis should be considered as an observation of publicly available information and not as investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Valiant Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VALIANTLAB across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (104.22%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (115.08%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (17.53x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (74.94%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-1.43%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.95%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 72.54x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Valiant Laboratories Ltd Financial Statements
Comprehensive financial data for Valiant Laboratories Ltd including income statement, balance sheet and cash flow
About VALIANTLAB (Valiant Laboratories Ltd)
Valiant Laboratories Ltd (VALIANTLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹367.80 (Cr). Valiant Laboratories Ltd has delivered a Return on Equity (ROE) of -1.43% and a ROCE of -0.95%. The debt-to-equity ratio stands at 0.17, reflecting the company's capital structure. Investors tracking VALIANTLAB share price can monitor key metrics including P/E ratio, promoter holding of 74.94%, and quarterly earnings growth.
Company Details
Key Leadership
VALIANTLAB Share Price: Frequently Asked Questions
What is the current share price of Valiant Laboratories Ltd (VALIANTLAB)?
As of 19 Feb 2026, 10:23 am IST, Valiant Laboratories Ltd share price is ₹58.51. The VALIANTLAB stock has a market capitalisation of ₹367.80 (Cr) on NSE/BSE.
Is VALIANTLAB share price Overvalued or Undervalued?
VALIANTLAB share price is currently trading at a P/E ratio of 72.54x, compared to the industry average of 31.77x. Based on this relative valuation, the Valiant Laboratories Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of VALIANTLAB share price?
The 52-week high of VALIANTLAB share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Valiant Laboratories Ltd share price?
Key factors influencing VALIANTLAB share price include quarterly earnings growth (Sales Growth: 115.08%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Valiant Laboratories Ltd a good stock for long-term investment?
Valiant Laboratories Ltd shows a 5-year Profit Growth of N/A% and an ROE of -1.43%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.17 before investing in VALIANTLAB shares.
How does Valiant Laboratories Ltd compare with its industry peers?
Valiant Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare VALIANTLAB share price P/E of 72.54x and ROE of -1.43% against the industry averages to determine competitive standing.
What is the P/E ratio of VALIANTLAB and what does it mean?
VALIANTLAB share price has a P/E ratio of 72.54x compared to the industry average of 31.77x. Investors pay ₹73 for every ₹1 of annual earnings.
How is VALIANTLAB performing according to Bull Run's analysis?
VALIANTLAB has a Bull Run fundamental score of 31.9/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does VALIANTLAB belong to?
VALIANTLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Valiant Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for VALIANTLAB?
VALIANTLAB has an ROE of -1.43%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Valiant Laboratories Ltd generates profits from shareholders capital.
How is VALIANTLAB debt-to-equity ratio and what does it indicate?
VALIANTLAB has a debt-to-equity ratio of 0.17, which indicates conservative financing with low financial risk.
What is VALIANTLAB dividend yield and is it a good dividend stock?
VALIANTLAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Valiant Laboratories Ltd shares.
How has VALIANTLAB share price grown over the past 5 years?
VALIANTLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in VALIANTLAB and why does it matter?
Promoters hold 74.94% of VALIANTLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Valiant Laboratories Ltd.
What is VALIANTLAB market capitalisation category?
VALIANTLAB has a market capitalisation of ₹368 crores, placing it in the Small-cap category.
How volatile is VALIANTLAB stock?
VALIANTLAB has a beta of N/A. A beta > 1 suggests the Valiant Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is VALIANTLAB operating profit margin trend?
VALIANTLAB has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is VALIANTLAB quarterly performance?
Recent quarterly performance shows Valiant Laboratories Ltd YoY Sales Growth of 115.08% and YoY Profit Growth of 104.22%.
What is the institutional holding pattern in VALIANTLAB?
VALIANTLAB has FII holding of 0.02% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Valiant Laboratories Ltd stock.